Varenicline for smoking cessation: efficacy, safety, and treatment recommendations
- PMID: 21049087
- PMCID: PMC2962400
- DOI: 10.2147/ppa.s10620
Varenicline for smoking cessation: efficacy, safety, and treatment recommendations
Abstract
Smoking is the leading preventable cause of morbidity and mortality in the US, and decreasing smoking prevalence is a public health priority. Patients achieve the greatest success when quit attempts involve behavioral therapy combined with pharmacotherapy. Varenicline is the most recent addition to the pharmacotherapeutic armamentarium for the treatment of tobacco dependence. Varenicline is efficacious and cost-effective. Smoking relapse and adverse treatment-related side effects may decrease medication adherence and patient satisfaction with varenicline. In the clinical setting, varenicline treatment can be optimized by reducing doses in patients who experience intolerable side effects, increasing the dose in partial responders, and providing long-term maintenance therapy for relapse prevention.
Keywords: nicotine addiction; smoking cessation; tobacco dependence; varenicline.
References
-
- Cigarette smoking among adults and trends in smoking cessation – United States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58(44):1227–1232. - PubMed
-
- Annual smoking-attributable mortality, years of potential life lost, and economic costs – United States, 1995–1999. MMWR Morb Mortal Wkly Rep. 2002;51(14):300–303. - PubMed
-
- Mackay J, Eriksen M. The Tobacco Atlas. Geneva, Switzerland: World Health Organization; 2002.
-
- Centers for Disease Control and Prevention The health consequences of smoking: A report of the Surgeon General. Available at: http://www.cdc.gov/tobacco/data_statistics/sgr/2004/index.htm. Accessed Aug 19, 2010. - PubMed
-
- Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238–1245. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
